|
Jul 29
|
Top Analyst Reports for Goldman Sachs, RTX & Regeneron
|
|
Jul 29
|
Countdown to Regeneron (REGN) Q2 Earnings: Wall Street Forecasts for Key Metrics
|
|
Jul 27
|
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
|
|
Jul 26
|
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
|
|
Jul 25
|
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
|
|
Jul 25
|
Trials to watch: Four biologics concluding pivotal COPD trials
|
|
Jul 24
|
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
|
|
Jul 8
|
3 No-Brainer Stocks to Buy in July
|
|
Jun 24
|
Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion
|
|
Jun 20
|
Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy?
|
|
Jun 18
|
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
|
|
Jun 17
|
Regeneron touts success with bispecific antibody in multiple myeloma trial
|
|
Jun 17
|
EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma
|
|
Jun 16
|
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
|
|
Jun 14
|
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea
|
|
Jun 14
|
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past five years
|
|
Jun 13
|
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
|
|
Jun 13
|
REGN, CI, BSX: Which “Strong Buy” Healthcare Stock Is the Best Bet?
|
|
Jun 12
|
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
|
|
Jun 11
|
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
|